BioSpace News Archive

Sebela Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) granted approval of SUFLAVE™ (polyethylene glycol, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), for colonoscopy preparation in adults.

CVRx, Inc. announced that it is set to join the Russell 2000 Index and the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 72,770 shares of Geron common stock as inducements to a newly hired employee in connection with commencement of employment with the Company.

NephroDI Therapeutics (NephroDI) announces today it has entered an agreement with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies which identifies and supports early-stage opportunities that can change the landscape of treatments for renal disorders and mental illness.

Sernova Corp., a clinical-stage company and leader in cell therapeutics, will be presenting updated interim data from its ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes and hypoglycemia unawareness at the American Diabetes Association 83rd Scientific Sessions, to be held June 23-26, 2023, in San Diego.

SK pharmteco, SK Inc.'s contract development manufacturing organization for pharmaceuticals, successfully completed its second facility for Cell and Gene Therapies manufacturing in Europe.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.

FUJIFILM Irvine Scientific, Inc. announced the addition of the Life Whisperer Genetics module to its Life Whisperer software package 1, enabling non-invasive evaluation of embryo genetic integrity during in vitro fertilization.

Huntsman Cancer Institute at the University of Utah, a pioneering innovator dedicated to developing more effective ways to care for and prevent cancer, announced plans for a new Huntsman Cancer Institute comprehensive cancer center in Utah County.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.